EB
Elite in Pancreatic Cancer

Dr. Erkut H. Borazanci

HonorHealth Research Institute
Scottsdale, AZ
Elite
 in Pancreatic Cancer
Specialties:Oncology | Gastroenterology
Experience:15 Years
Clinical Trials:Currently Recruiting for 11 Trials
Accepts:New PatientsMedicare
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Erkut H. Borazanci's experience treating your condition:
About Dr. Erkut H. Borazanci

Erkut Borazanci is an Oncologist and a Gastroenterologist in Scottsdale, Arizona. Borazanci has been practicing medicine for over 15 years and is rated as an Elite expert by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 10 other conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, and Pancreatoblastoma. He is licensed to treat patients in Arizona. Borazanci is currently accepting new patients.

His clinical research consists of co-authoring 37 peer reviewed articles and participating in 25 clinical trials in the past 15 years. In particular, he has co-authored 29 articles and participated in 17 clinical trials in the study of Pancreatic Cancer.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Erkut H. Borazanci it is best to call his office and ask if your insurance is accepted.

Accepts Medicare
Call to see if your plan is accepted.
Locations
10510 N 92nd St, Scottsdale, AZ 85258
Background & Education
Graduate Institution
Louisiana State University School Of Medicine In Shreveport, 2008
Specialties
Oncology
Gastroenterology
Licenses
Internal Medicine in AZ
Hospital Affiliations
HonorHealth Scottsdale Shea Medical Center
HonorHealth Deer Valley Medical Center
HonorHealth Scottsdale Thompson Peak Medical Center
HonorHealth Scottsdale Osborn Medical Center
HonorHealth Sonoran Crossing Medical Center
HonorHealth John C Lincoln Medical Center
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials
An Early Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEEL-224 in Patients With Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: October 21, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Dose-escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: October 20, 2022
Intervention Type: Drug
Study Phase: Phase 1
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Enrollment Status: Recruiting
Publish Date: October 13, 2022
Intervention Type: Drug
Study Drugs: ONC-392Pembrolizumab
Study Phase: Phase 1/Phase 2
Efficacy and Safety of Pemigatinib in Subjects With Advanced Metastatic or Surgically Unresectable Adenosquamous Carcinoma of the Pancreas (ASCP) Who Have Progressed On Previous Therapy
Enrollment Status: Recruiting
Publish Date: August 10, 2022
Intervention Type: Drug
Study Drug: Pemigatinib
Study Phase: Phase 2
A Phase II Pilot Clinical Trial of Lurbinectedin (Zepzelca™ PM01183) in Patients With Advanced Pancreatic Cancer With DNA Repair Mutations
Enrollment Status: Recruiting
Publish Date: August 10, 2022
Intervention Type: Drug
Study Drug: Lurbinectedin [Zepzelca]
Study Phase: Phase 2
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of CPI-300 Via Intravenous Infusion in Patients With Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: July 20, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase Ib/II Study of the Microenvironment Modifier L-DOS47 Plus Doxorubicin for the Treatment of Patients With Previously Treated Advanced Pancreatic Cancer
Enrollment Status: Recruiting
Publish Date: June 14, 2022
Intervention Type: Drug, Biological
Study Drugs: L-DOS47Doxorubicin
Study Phase: Phase 1/Phase 2
The Seena Magowitz Phase IB/II Trial of CMP-001 (a TLR9 Agonist) in Combination With INCAGN01949 (an Activating Anti-OX40 Antibody) for In Situ Intratumoral Injection for Patients With Stage IV Pancreatic and Other Cancers Except Melanoma
Enrollment Status: Recruiting
Publish Date: June 03, 2022
Intervention Type: Biological, Drug
Study Drugs: Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949VLP-encapsulated TLR9 Agonist CMP-001
Study Phase: Phase 1/Phase 2
A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin+ Hydroxychlororoquine as Preoperative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas
Enrollment Status: Recruiting
Publish Date: May 16, 2022
Intervention Type: Drug
Study Drugs: Paclitaxel protein boundGemcitabineCisplatinHydroxychloroquine
Study Phase: Phase 2
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: April 06, 2022
Intervention Type: Drug
Study Drug: Minnelide™Capsules
Study Phase: Phase 1
A Phase II Trial of Vemurafenib in Combination With Sorafenib to Treat Patients With Advanced KRAS G12D Mutated Pancreatic Cancer: Targeting RAF Dimers to Suppress Oncogenic RAS Signaling (The Dr. Nate Nieto Study)
Enrollment Status: Recruiting
Publish Date: November 03, 2021
Intervention Type: Drug
Study Drugs: VemurafenibSorafenib
Study Phase: Phase 2
A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
Enrollment Status: Active, not recruiting
Publish Date: October 19, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Drugs: OlaratumabNab-paclitaxelGemcitabine
Study Phase: Phase 1/Phase 2
A Randomized, Open Label, Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: May 03, 2022
Intervention Type: Drug
Study Drugs: FG-3019GemcitabineNab-paclitaxel
Study Phase: Phase 1/Phase 2
A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study
Enrollment Status: Active, not recruiting
Publish Date: April 28, 2022
Intervention Type: Drug
Study Drugs: BL-8040PembrolizumabChemotherapy of Onivyde
Study Phase: Phase 2
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant VaccineNivolumabPembrolizumab
Study Phase: Phase 1/Phase 2
A Phase II Pilot Trial of Nivolumab + Albumin-Bound Paclitaxel + Paricalcitol + Cisplatin + Gemcitabine (NAPPCG) In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Enrollment Status: Active, not recruiting
Publish Date: March 03, 2022
Intervention Type: Drug
Study Drugs: NivolumabAlbumin-bound paclitaxelParicalcitolCisplatinGemcitabine
Study Phase: Phase 2
A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Paricalcitol as Pre-operative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas
Enrollment Status: Active, not recruiting
Publish Date: February 17, 2022
Intervention Type: Drug
Study Drug: Paclitaxel protein bound
Study Phase: Phase 2
A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NABPLAGEMD)
Enrollment Status: Active, not recruiting
Publish Date: February 17, 2022
Intervention Type: Drug
Study Drug: Paricalcitol 
Study Phase: Phase 2
An Exploratory Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 1
A SU2C Catalyst ® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response
Enrollment Status: Completed
Publish Date: October 08, 2020
Intervention Type: Drug
Study Phase: Phase 2
MinPAC: A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer.
Enrollment Status: Completed
Publish Date: September 02, 2020
Intervention Type: Drug
Study Phase: Phase 2
Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer in Consecutive Cases Unselected for Family History
Enrollment Status: Completed
Publish Date: August 25, 2020
Intervention Type: Genetic
A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
Enrollment Status: Completed
Publish Date: February 11, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b Dose-Escalation and Cohort-Expansion Study of the Safety, Tolerability, and Efficacy of a Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With the Anti-PD-L1 Antibody Durvalumab (MEDI4736) in Recurrent or Refractory Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: August 05, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 14 Less Clinical Trials -
37 Total Publications
Addendum: The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series.
Journal: Oncotarget
Published: October 26, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
TB
Dr. Tanios Bekaii
Oncology
Mayo Clinic - Arizona
Elite
Highly rated in
24
conditions
Oncology
Mayo Clinic - Arizona

Mayo Clinic

Mayo Clinic - Arizona

5777 E Mayo Blvd, 
Phoenix, AZ 
 6.9 mi

Tanios Bekaii is an Oncologist in Phoenix, Arizona. Bekaii has been practicing medicine for over 31 years and is rated as an Elite expert by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 24 other conditions, according to our data. His top areas of expertise are Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, and Pancreatic Ductal Adenocarcinoma. He is licensed to treat patients in Arizona.

TD
Tomislav Dragovich
Dr. Tomislav Dragovich
Oncology | Hematology Oncology
Elite
Highly rated in
17
conditions
Oncology
Hematology Oncology

Banner Health

Banner MD Anderson Cancer Center Clinic

2946 E Banner Gateway Dr, 
Gilbert, AZ 
 16.6 mi

Tomislav Dragovich is an Oncologist and a Hematologist Oncology expert in Gilbert, Arizona. Dragovich has been practicing medicine for over 35 years and is rated as a Distinguished expert by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 17 other conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, and Familial Colorectal Cancer. He is licensed to treat patients in Arizona. Dragovich is currently accepting new patients.

MB
Dr. Mitesh J. Borad
Hematology | Oncology | Hematology Oncology
Mayo Clinic - Arizona
Distinguished
Highly rated in
20
conditions
Hematology
Oncology
Hematology Oncology
Mayo Clinic - Arizona

Mayo Clinic

Mayo Clinic - Arizona

5777 E Mayo Blvd, 
Phoenix, AZ 
 6.9 mi

Mitesh Borad is a Hematologist and an Oncologist in Phoenix, Arizona. Borad has been practicing medicine for over 23 years and is rated as an Elite expert by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 20 other conditions, according to our data. His top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Gallbladder Cancer, Pancreatic Cancer, and Liver Cancer. He is licensed to treat patients in Louisiana, California, and Arizona. Borad is currently accepting new patients.